VCYT News and Press, Veracyte Inc. From 04/22/24

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at ...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for ident...

2024-04-19 03:54:17 ET Summary ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, making up around 20% of the assets. ARK Invest ...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in S...

2024-04-15 11:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...

2024-04-05 13:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-05 22:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN * Clinical Practice Guidelines in Oncology (NCCN Guidel...

2024-02-22 21:24:07 ET Veracyte, Inc. (VCYT) Q4 2023 Earnings Conference Call February 22, 2024 04:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Office...